NovoCure Limited (NVCR)
Market: NASD |
Currency: USD
Address: No. 4 The Forum
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
📈 NovoCure Limited Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$32.57
-
Upside/Downside from Analyst Target:
93.88%
-
Broker Call:
10
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
10-25%
-
Net Income Growth Range (1Y):
10-25%
-
Revenue Growth Range (1Y):
10-25%
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for NovoCure Limited
Date | Reported EPS |
---|
2025-04-24 | - |
2025-04-24 | -0.31 |
2025-02-27 | -0.61 |
2024-10-30 | -0.28 |
2024-07-25 | -0.31 |
2024-05-02 | -0.36 |
2024-02-22 | -0.45 |
2023-10-26 | -0.46 |
2023-07-27 | -0.54 |
2023-05-04 | -0.5 |
2023-02-23 | -0.36 |
2022-10-27 | -0.25 |
2022-07-28 | -0.23 |
2022-04-28 | -0.04 |
2022-01-10 | -0.25 |
2021-10-28 | -0.13 |
2021-07-29 | -0.14 |
2021-04-29 | -0.04 |
2021-02-25 | 0.04 |
2020-10-29 | 0.09 |
2020-07-30 | 0.02 |
2020-04-30 | 0.04 |
2020-02-27 | 0.04 |
2019-10-31 | 0.02 |
2019-07-25 | -0.01 |
2019-05-02 | -0.13 |
📰 Related News & Research
No related articles found for "novocure limited".